Scientists turn plastic bottles into Parkinson’s drug using engineered bacteria in breakthrough medical recycling discovery
Plastic waste has long been viewed as one of the world's most persistent environmental challenges. Yet researchers have now demonstrated a remarkable way to transform that problem into something potentially life-changing. In a pioneering study, scientists engineered bacteria capable of converting di
By Toi Science Desk
Plastic waste has long been viewed as one of the world's most persistent environmental challenges.
Yet researchers have now demonstrated a remarkable way to transform that problem into something potentially life-changing.
In a pioneering study, scientists engineered bacteria capable of converting discarded polyethylene terephthalate (PET) plastic bottles into levodopa (L-DOPA), the most widely used treatment for Parkinson’s disease.
The achievement represents the first time a biological process has been engineered to turn post-consumer plastic waste directly into a therapeutic drug for a neurological condition.
Beyond its medical significance, the work highlights how waste materials can become valuable carbon sources for pharmaceutical manufacturing, potentially reducing dependence on fossil-fuel-derived feedstocks while addressing growing concerns over plastic pollution.
Although the technology remains at an early stage and has not yet been scaled for commercial production, it offers a compelling glimpse into a future where rubbish becomes medicine.How engineered bacteria transformed waste plastic into a Parkinson’s disease treatmentThe breakthrough was achieved by researchers at the University of Edinburgh, who developed genetically engineered Escherichia coli capable of converting PET-derived molecules into levodopa (L-DOPA), a frontline medication used to manage Parkinson’s disease symptoms.
The process begins by breaking down PET plastic into terephthalic acid, a chemical building block that the engineered microbes can metabolise and transform through a series of biological reactions.
The resulting process produced high levodopa yields under mild aqueous conditions, demonstrating the feasibility of converting plastic waste into a pharmaceutical compound.According to the study ‘Microbial upcycling of plastic waste to levodopa’:“We report the bio-upcycling of poly(ethylene terephthalate) (PET) plastic waste into levodopa (L-DOPA), a frontline medication for Parkinson’s disease, using engineered Escherichia coli.”The researchers also addressed key technical barriers, including substrate transport and metabolic feedback inhibition, enabling the bacteria to efficiently channel carbon from waste plastic into medicine.
The team reported levodopa titres reaching 5.0 g l⁻¹ and successfully isolated pharmaceutical-grade product from both industrial PET waste and a single post-consumer plastic bottle.Why this plastic-to-medicine breakthrough could change sustainable pharmaceutical manufacturingTraditional pharmaceutical production often relies on fossil-fuel-derived raw materials and energy-intensive chemical processes.
The Edinburgh team's approach demonstrates how engineering biology can reclaim carbon already embedded within waste streams and redirect it towards high-value medical products.Lead researcher Professor Stephen Wallace highlighted the broader implications of the technology:“Plastic waste is often seen purely as an environmental problem, but it is also a vast and largely untapped source of carbon.”He added:“If we can create medicines for neurological disease from a waste plastic bottle, it is exciting to imagine what else this technology could achieve.”The findings illustrate the growing potential of "bio-upcycling", a process that transforms low-value waste into products with significantly higher economic and societal value.
Researchers suggest similar strategies could eventually be applied to produce other pharmaceuticals, chemicals and speciality materials from waste-derived feedstocks.What the research means for Parkinson’s disease treatment and future drug productionLevodopa remains the gold-standard treatment for Parkinson’s disease because it serves as a direct precursor to dopamine, helping replenish declining dopamine levels in the brain.
Researchers describe L-DOPA as the frontline medication for managing the condition's motor symptoms.While the new manufacturing approach does not alter how patients use the drug, it introduces a potentially more sustainable pathway for producing an essential medicine.
However, scientists caution that the process remains at the proof-of-concept stage.
Significant work is still required to improve efficiency, scale production and assess commercial viability before industrial adoption becomes realistic.Nevertheless, the study demonstrates a powerful concept: materials traditionally regarded as waste can be reimagined as resources for advanced healthcare.
By combining synthetic biology, microbial engineering and circular manufacturing principles, researchers have opened a new frontier where environmental remediation and pharmaceutical innovation work hand in hand.